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The methylerythritol phosphate (MEP) pathway is essential in most prokaryotes and some
lower eukaryotes but absent from human cells, and is a validated target for antimicrobial
drug development. The formation of MEP is catalyzed by 1-deoxy-d-xylulose 5-phosphate
reductoisomerase (DXR). MEP pathway genes have been identified in many category A and
B biothreat agents, including Francisella tularensis, which causes the zoonosis tularemia.
Fosmidomycin (Fos) inhibits purified Francisella DXR. This compound also inhibits the
growth of F. tularensis NIH B38, F. novicida and F. tularensis subsp. holarctica LVS bacteria.
Related compounds such as FR900098 and the lipophilic prodrug of FR900098 (compound
1) have been developed to improve the bioavailability of these DXR inhibitors. In perform-
ing disk-inhibition assays with these compounds, we observed breakthrough colonies of
F. novicida in the presence of Fos, suggesting spontaneous development of Fos resis-
tance (FosR). FosR bacteria had decreased sensitivity to both Fos and FR900098. The two
most likely targets for the development of mutants would be the DXR enzyme itself or the
glycerol-3-phosphate transporter (GlpT) that allows entry of Fos into the bacteria. Sensitivity
of FosR F. novicida bacteria to compound 1 was not abated suggesting that spontaneous
resistance is not due to mutation of DXR. We thus predicted that the glpT transporter
may be mutated leading to this resistant phenotype. Supporting this, transposon insertion
mutants at the glpT locus were also found to be resistant to Fos. DNA sequencing of
four different spontaneous FosR colonies demonstrated a variety of deletions in the glpT
coding region. The overall frequency of FosR mutations in F. novicida was determined to
be 6.3×10−8. Thus we conclude that one mechanism of resistance of F. novicida to Fos
is caused by mutations in GlpT. This is the first description of spontaneous mutations in
Francisella leading to FosR.
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INTRODUCTION
Francisella tularensis is the etiologic agent of tularemia, a zoonotic
disease that occurs in much of the northern hemisphere includ-
ing North America. Its potential use as a biological weapon has
given this zoonotic organism much attention (Foley and Nieto,
2010). Ulceroglandular forms of the disease can be contracted by
humans following interaction with small rodents and lagomorphs,
as well as through mechanical and vector transmission by biting
arthropods (Akimana and Kwaik, 2011; Potz-Biedermann et al.,
2011). In addition, pneumonic cases of tularemia are occasionally
seen in humans following inhalation of aerosols containing the
bacteria (Matyas et al., 2007; Ojeda et al., 2008). The outcome of
these various forms of disease is determined by the availability of
prompt treatment with a variety of antibiotics (Ikaheimo et al.,
2000; Greenfield and Bronze, 2004). These small, Gram-negative
coccobacilli are susceptible to treatment with antimicrobial agents,
including streptomycin, gentamicin, doxycycline, quinolones, and
chloramphenicol (Scheel et al., 1992; Ikaheimo et al., 2000; Johans-
son et al., 2002). F. tularensis subsp. holarctica, which is found in
the northern parts of Europe and Asia, consists of Biovars I and
II that are susceptible or resistant to erythromycin, respectively
(Kudelina and Olsufiev, 1980; Gestin et al., 2010). Resistance to
penicillin-class β-lactams has been routinely demonstrated from
naturally occurring isolates of Francisella due to the expression of
β-lactamase (Bina et al., 2006).
The methylerythritol phosphate (MEP) pathway is essential in
most prokaryotes and some lower eukaryotes but absent from
human cells, and is a validated target for antimicrobial drug
development (Wiemer et al., 2010). The formation of MEP is
catalyzed by 1-deoxy-d-xylulose 5-phosphate reductoisomerase
(DXR). MEP pathway genes have been identified in many cat-
egory A and B biothreat agents, including F. tularensis, Bacillus
anthracis, and Yersinia pestis. There are two well-known inhibitors
of DXR, an enzyme responsible for the formation of MEP used
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for the down-stream synthesis of the isoprenoids (Jawaid et al.,
2009). One is fosmidomycin (Fos, 3-[formyl(hydroxy) amino]
propylphosphonic acid), currently in clinical trials for treatment
of malaria (Wiesner et al., 2003), and the second is FR900098
(3-[acetyl(hydroxy)amino] propylphosphonic acid). We have pre-
viously demonstrated that Fos inhibits Francisella growth and
can target purified Francisella DXR enzyme (Jawaid et al., 2009).
Because the MEP pathway is found in most prokaryotes and lower
eukaryotes, but not in humans, and is essential for survival of these
organisms, it has been described as a validated target for the devel-
opment of new antimicrobial therapies (Rodriguez-Concepcion,
2004; Singh et al., 2007; Davey et al., 2011).
The glycerol-3-phosphate transporter (GlpT) system has been
well characterized in E. coli, B. subtilis, and Pseudomonas aerugi-
nosa (Nilsson et al., 1994; Lemieux et al., 2005; Castaneda-Garcia
et al., 2009). GlpT is a member of the Major Facilitator Super-
family (MFS) that functions as an antiporter moving glycerol-3-
phosphate into the cell, and exporting intracellular phosphate. In
E. coli, the structure of the transporter consists of 12 membrane-
spanning sections in alpha-helix form, joined together on the
cytoplasmic side by an extended loop structure (Lemieux et al.,
2005). A similar arrangement is predicted for Francisella GlpT.
We have previously shown that the Francisella genome contains
glpT, and that Fos effectiveness is mediated by the action of this
transporter (McKenney et al., in press). The polar nature of Fos
requires it be transported across the bacterial cell membrane via
a transporter such as GlpT. Organisms that have DXR but lack
such transporters, such asMycobacterium tuberculosis andBrucella
abortus, cannot transport Fos, and thus are functionally resis-
tant (Brown and Parish, 2008; Sangari et al., 2010). However,
when E. coli GlpT is expressed in B. abortus, Fos is transported
into the bacterial cell, interacts with the DXR-like enzyme, and
leads to decreased bacterial growth (Sangari et al., 2010). A series
of acyloxyalkyl ester prodrug derivatives of FR900098, including
compound 1 (Figure 1), have been generated which are cleaved to
FR900098 by the bacterial esterases. They are more lipophilic in
nature, demonstrate improved in vitro activity against M. tubercu-
losis (Uh et al., 2011), and improved in vivo activity (Ortmann
et al., 2003) against malaria. We have demonstrated that the
lipophilic prodrug of FR900098, compound 1, is able to bypass
the Fos transporter and exert antimicrobial effects regardless of
mutations in glpT that lead to Fos resistance (FosR; McKenney et
al., in press).
Francisella species are not known to be highly multi-drug resis-
tant, or to rapidly develop resistance. Francisella are susceptible
to many common antibiotics, except penicillins (Ikaheimo et al.,
2000; Urich and Petersen, 2008). Francisella has two TolC-like pro-
teins, TolC and the highly related FltC (Gil et al., 2006); mutations
in these genes increase the sensitivity of F. tularensis LVS to vari-
ous antibiotics, suggesting at least some role for drug efflux in the
baseline sensitivity of Francisella to antibiotics. The sensitivity to
macrolides varies between Francisella strains (Ahmad et al., 2010).
F. tularensis LVS has a point mutation in Domain V of the 23S
rRNA, rendering it more resistant to erythromycin than F. novicida
orF. tularensis Schu S4 (Biswas et al., 2008). In the North American
Type A Francisella strains, erythromycin MICs range from 0.5 to
4µg/ml, whileF. tularensis LVS has an MIC> 256µg/ml (Marinov
et al., 2009). Spontaneous antibiotic resistance to spectinomycin
has been reported in Francisella at a low frequency of incidence
(Kormilitsyna and Marakusha, 1983).
Here we report the spontaneous development of a Fos-resistant
phenotype in Francisella. Spontaneous FosR has not been previ-
ously reported for this organism, and it is of concern to have a
biothreat agent spontaneously acquire resistance to new classes of
antibiotics. Thus we sought to understand the mechanism of FosR
in Francisella.
MATERIALS AND METHODS
STRAINS AND GROWTH OF BACTERIA
Francisella tularensis subsp. novicida Utah 112 (F. novicida; BEI
Resources # NR13) was grown in trypticase soy broth with 0.1%
cysteine HCl (TSB-C), on TSB-C agar plates, or Chocolate II Agar
plates (CHAB – BD Biosciences) as noted for each assay. F. tularen-
sis subsp. tularensis NIH B38 (ATCC 6223; BEI Resources # NR50,
deposited as the type strain for F. tularensis tularensis) was grown
on TSB-C agar plates at 37˚C with 5% CO2 for 48 h, harvested
by scraping into 20% glycerol, and stored at −80˚C. Francisella
on plates was grown at 37˚C in an atmosphere of 5% CO2.
FIGURE 1 | Structure of inhibitors used in this study. (1) Fosmidomycin
(Fos, 3-[formyl(hydroxy) amino] propylphosphonic acid). (2) FR900098
(3-[acetyl(hydroxy)amino] propylphosphonic acid). (3) Compound 1:
acyloxyalkyl ester prodrug derivative of FR900098 (Ortmann et al., 2003).
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Minimum inhibitory concentration (MIC) assays were performed
in cation-adjusted Mueller–Hinton broth (MHB) according to the
guidelines published by the Clinical and Laboratory Standards
Institute; M11-A7.
Transposon insertion mutants in the glpT locus [FTN_0636; F.
novicida tnfn1_pw060323p08q150 BEI Catalog #NR-5683 and F.
novicida tnfn1_pw060418p01q161 BEI Catalog #NR-6558, both
Type T20 (ISFn2/FRT)] (Gallagher et al., 2007) were obtained
through the NIH Biodefense and Emerging Infectious Disease
Research Repository, NIAID, NIH: F. novicida,“Two-Allele”Trans-
poson Mutant Library. F. novicida U112 glpT-1 and glpT-2 (data
not shown) transposon insertion mutants were grown as above,
but in the presence of kanamycin (10µg/ml) to select for the
mutants. Sequences for the transposon mutants are shown in
Figure A1 in Appendix (Gallagher et al., 2007).
PREPARATION OF STOCK SOLUTIONS OF Fos, FR900098, AND
COMPOUND 1
All inhibitor stocks were made at high starting concentration
between 10 and 20 mg/ml. Fos sodium salt (Invitrogen #F-23103)
and FR900098 monosodium salt (Sigma–Aldrich # F8307) were
obtained as dry powders and were dissolved in water. Compound
1 (kind gift from C. Dowd) was dissolved in 100% DMSO to the
final concentrations indicated.
DISK-INHIBITION ASSAY
Following the Kirby–Bauer disk diffusion assay protocols (Bauer
et al., 1966), inhibitor-saturated disks were placed on a lawn of
bacteria to display a zone of growth inhibition around the disk
indicating susceptibility. A concentration of an overnight cul-
ture of bacteria equal to a 0.5 McFarland standard was spread
on Chocolate II Agar plate (BD Biosciences) using a sterile cot-
ton swab. Inhibitor disks were made by absorbing 20µl of each
inhibitor stock (10 mg/ml) to a sterile, thick Whatman filter paper
6-mm disk, so that each disk contained 200µg. Three disks of the
same inhibitor were added to each plate, except for NIHB38, for
which only one disk was used per plate. For NIHB38 experiments,
both 200 and 100µg per disk were tested. The plates were wrapped
in tin foil to protect the inhibitors from light and placed in the
37˚C incubator for 48 h. The zone of inhibition was determined
by measuring the diameter of the zone of no growth, including
the 6-mm disk. Each zone was measured three times at different
points of the zone (n= 9). A 6-mm zone of inhibition indicates
no inhibition.
MIC ASSAYS FOR FOS AND LIPOPHILIC ANALOGS AGAINST WILD-TYPE
F. NOVICIDA U112 AND TRANSPOSON INSERTION MUTANTS OF GLPT
In accordance with CLSI standards, 150µl cation-adjusted MHB
was inoculated with 1.5× 105 CFU of F. novicida. For MIC assays
against wild-type F. novicida, each well of column 1 was amended
with 150µl of Fos or compound 1 to achieve a final concentration
of 300 and 200µg/ml, respectively. Subsequent MIC assays had a
starting concentration of 200µg/ml regardless of the compound
tested. Twofold serial dilutions of column 1 were performed to fill
columns 2–11 of a 96-well plate. For compound 1, DMSO vehi-
cle control wells were included in side-by-side assays. Column 12
received no drug and acts as the positive growth control for the
assay. Absorbances (A600) were read for each well before incuba-
tion to record background. Plates were incubated at 37˚C plus 5%
CO2,A600 were determined at 24 and 48 h, and IC50 and MIC were
determined.
GENOMIC DNA PREPARATION, PCR AMPLIFICATION, AND
SEQUENCING
Overnight cultures were centrifuged to form bacterial pellets
and supernatants were removed. Genomic DNA was prepared
using the Wizard Genomic DNA kit (Promega, Madison, WI,
USA). Briefly, pellets were re-suspended in 400µl of nuclei
lysis solution and incubated at 80˚C for 15 min to lyse bacte-
ria. Total DNA concentrations were analyzed using the Nan-
odrop spectrophotometer (Thermo Scientific, Wilmington, DE,
USA) and adjusted to 40 ng/µl. Primers used for PCR con-
firmation that colonies were indeed F. novicida were designed
to amplify 16S rRNAs (16SrRNAF: CTGTCGTCAGCTCGT-
GTTGT; 16SrRNA R: CGTAAGGGCCATGATGACTT; Forsman
et al., 1994). Primers used to amplify the entire ORF of the
glpT gene (glpTF: AACAGCGGTTTAGCTATTTTCAA; glpTR:
TGCAATCTGAGCTGACTGAAG) were designed using Primer
3 through the National Center for Biotechnology Information
(NCBI). Real-time PCR was performed on the Biorad MyIQ
instrument with iQ SYBR Green Supermix in 50µl reactions
(Biorad, Hercules, CA, USA). Thermal cycler profile was set to
95˚C for 3 min for initial denaturation and enzyme activation fol-
lowed by 40 cycles of 95˚C for 10 s and 55˚C for 30 s. Sequencing
primers were the same as the ORF amplification primers, but
were synthesized and used by Functional Biosciences (Madison,
WI, USA).
SPONTANEOUS MUTATION FREQUENCY FOR FosR
A stock culture of F. novicida U112 was grown in TSB-C broth
overnight at 37˚C with continuous shaking at 165 rpm. Viable bac-
teria from overnight cultures were enumerated by serial dilution in
sterile phosphate-buffered saline (PBS) and plated on TSB-C non-
selective agar plates. TSB-C plates were incubated for >24 h, and
colony forming units were counted to determine bacterial density
of the culture. A diluted subculture was created to achieve a final
concentration of 1× 103 CFU/ml. Parallel cultures prepared as
1 ml aliquots from the subculture (1× 103 CFU) were incubated
overnight at 37˚C with continuous shaking at 165 rpm (Rosche
and Foster, 2000). The number of mutations that resulted in FosR
was determined by plating 0.1 ml aliquots of the parallel cultures
(n= 5) on TSB-C plates containing 122µM (25µg/ml) Fos. The
total number of bacteria in the cultures was determined by serial
dilution and plating on non-selective media (Rosche and Foster,
2000).
RESULTS
We have previously reported the in vitro antimicrobial activity of
Fos and FR900098 (Figure 1) against Francisella, and the inhi-
bition of purified Francisella DXR enzyme by these compounds
(Jawaid et al., 2009; McKenney et al., in press). We have also
demonstrated that a lipophilic prodrug of FR900098 (compound
1) is able to bypass the GlpT transporter and exert antimicrobial
effects regardless of mutations in glpT that lead to FosR, and that
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compound 1 is effective in an in vivo model of F. novicida infection
(McKenney et al., in press).
WILD-TYPE F. novicida
The Kirby–Bauer disk-inhibition assay was used to determine the
susceptibility of wild-type F. novicida U112 to Fos and FR900098.
The zone of inhibition around the disk containing 200µg of Fos
was 37± 1 mm (Figure 2A). The zone of inhibition around the
disk containing 200µg of FR900098 was 29± 2 mm (Figure 2C).
ForF. tularensis NIHB38, the type strain for Type A tularemia, both
of these compounds lead to a large zone of inhibition. For a disk
with 100µg Fos, the zone of inhibition for F. tularensis NIHB38
was 72± 2 mm (data not shown), suggesting thatF. tularensis Type
A strains are sensitive to Fos. A zone of inhibition of 6 mm (the
size of the disk) indicated no inhibition, which was observed for a
water-only disk (data not shown).
SPONTANEOUS FosR MUTANTS
While performing the Kirby–Bauer disk-inhibition assay with F.
novicida against Fos and FR900098, breakthrough colonies were
observed growing inside the zone of inhibition (Figure 2A – Fos,
Figure 2C – FR900098). However, the zone of inhibition is still
clearly defined. The colonies within the zone of inhibition are
slightly different in their appearance than the wild-type F. novicida
that is growing outside the zone of inhibition. The colonies are
slightly larger and more mucoid, but are the same color as the wild-
type colonies. These colonies (from Figures 2A,C) were confirmed
to be F. novicida by real-time PCR using F. novicida specific 16S
rRNA primers (Forsman et al., 1994; data not shown). Numerous
breakthrough colonies were also observed for F. tularensis NIHB38
with both of these compounds, indicating that this “type strain”
for F. tularensis Type A strains may also develop spontaneous
resistance to Fos.
Based on our results in the disk-inhibition assay as well as
our previous studies (McKenney et al., in press), we hypothe-
sized that the two most likely bacterial targets for the development
of mutants would be mutations of the DXR enzyme itself or
mutations of GlpT that allow entry of Fos into the bacteria.
MICs FOR WILD-TYPE AND FosR MUTANTS
We found that FosR mutants are resistant to Fos but are sensitive to
compound 1, the lipophilic prodrug of FR900098. The MIC for Fos
FIGURE 2 | Disk-inhibition assay. Each disk contains 200µg of
antibiotic. (A)Wild-type F. novicida has a 37±1-mm zone of
inhibition around the disk containing fosmidomycin with multiple
breakthrough colonies shown. (B) GlpT-1 transposon mutant of F.
novicida is completely resistant to fosmidomycin (zone of
inhibition=6 mm). (C)Wild-type F. novicida has a 29±2-mm zone
of inhibition around the disk containing FR900098. Breakthrough
colonies can also be seen in the inhibition zone. (D) GlpT-1
transposon mutant of F. novicida has intermediate resistance to
FR900098 (zone of inhibition=15 mm), but does not demonstrate
any breakthrough colonies. This experiment was performed three
times, with representative examples shown.
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against wild-type F. novicida is 121µM (IC50 is 0.101µg/ml with
a 95% confidence interval (CI)= 0.079–0.130 mg/l; Figure 3A).
The MIC for the lipophilic compound 1 against F. novicida
is 100µg/ml or 203µM (IC50 is 11.99µg/ml, 95% CI= 9.84–
14.62µg/ml; Figure 3B). A Fos-resistant colony (FosR#2) isolated
from our disk-inhibition assays was grown overnight as described,
and the MICs and IC50s of Fos and compound 1 were determined.
Concentrations of inhibitor used in this assay ranged from 0.4
to 200µg/ml. FosR#2-resistant bacteria grew well at all concentra-
tions of Fos tested, with significant growth in all wells at or near
the levels of no-drug control (Figure 3C). Conversely, the MIC of
compound 1 for FosR#2 was 100µg/ml or 203µM (IC50 of com-
pound 1 for FosR#2 is 24.38µg/ml, 95% CI= 18.75–31.70µg/ml;
Figure 3D). The MIC was identical between wild-type and FosR#2
and the IC50s were very close. The IC50 curves can almost be
superimposed.
IS DXR MUTATED IN FosR BACTERIA?
Fosmidomycin-resistant bacteria retained sensitivity to com-
pound 1. Since compound 1 is a lipophilic prodrug it will get
metabolized to FR900098 inside the bacteria, which will then
target bacterial DXR. This suggests that spontaneous resistance
is not due to mutation of DXR, since FosR bacteria are inhibited
by compound 1. No transposon insertion mutants are available for
DXR as this enzyme is thought to be essential toFrancisella growth,
so the role of DXR could not be directly tested in this study. We
thus hypothesized that the mutations that lead to the Fos-resistant
phenotype are not mutations in DXR. We then predicted that the
GlpT transporter may be mutated, leading to this resistant phe-
notype. Supporting this, transposon insertion mutants at the glpT
locus were also found to be resistant to Fos.
DISK INHIBITION WITH glpT TRANSPOSON INSERTION MUTANTS
The susceptibility of the glpT transposon insertion mutants to
Fos and FR900098 was also tested in this manner. There was no
inhibition of the glpT transposon mutant by Fos (Figure 2B),
supporting the critical role of glpT in Fos transport across the bac-
terial membranes in order for it to reach the DXR enzyme target
inside the bacteria. glpT mutants with FR900098 disks demon-
strated intermediate inhibition (15± 1 mm zone; Figure 2D).
This effect of FR900098 on the glpT mutant is consistent with
our previous studies and published reports suggesting improved
FIGURE 3 | Minimum inhibitory concentration assay for F.
novicida and FosR#2 mutant.Wild-type F. novicida susceptibility to
fosmidomycin (A) and compound 1 (B). Wild-type MIC for
fosmidomycin is 121µM. [WT IC50 for fosmidomycin is 0.092 mg/l
(95% CI=0.079–0.107 mg/l)]. Wild-type MIC for compound 1 is
203µm. Wild-type IC50 for compound 1 is 11.99 mg/l (95%
CI=9.84–14.62 mg/l, R2 = 0.972). FosR#2 mutant resistance to
fosmidomycin (C) FosR#2 and susceptibility to compound 1 (D). F.
novicida glpT mutant MIC or IC50 for fosmidomycin could not be
defined due to lack of inhibition (R2 value for fitness=0.38). FosR#2
mutant MIC for compound 1 is approximately 203µM. The IC50 for
compound 1 is 24.38 mg/l (95% CI=18.75–31.70 mg/l, R2 =0.944).
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bacterial penetration of this compound (McKenney et al., in
press). Interestingly, as can be seen in Figure 2D, there were no
breakthrough colonies observed in the glpT transposon mutant
experiments in multiple repeats, perhaps suggesting that the
locus was the origination of the instability, leading to the break-
through colonies observed with the wild-type F. novicida, and that
other loci are perhaps not as susceptible to mutations leading to
breakthrough colonies.
ANTIBIOTIC SENSITIVITY OF glpT TN MUTANTS
glpT transposon mutants are resistant to Fos and sensitive to
compound 1. The glpT transposon insertion mutants were tested
for their susceptibility to Fos and compound 1 in a liquid broth
growth inhibition assay. As expected, the transporter-independent
lipophilic prodrug compound 1 was effective at inhibiting growth
of the glpT transposon insertion mutants (glpT-1 shown) as well
as wild-type F. novicida, while Fos at twice the MIC was not
(Figure 4). This result supports the hypothesis that mutation in the
glpT transporter sequence can have a significant detrimental effect
on transport of Fos across the bacterial membrane, preventing its
interaction with the intended target enzyme, DXR. Intermediate
inhibition of the glpT mutant by FR900098 was observed in this
assay (gray bars) consistent with the disk-inhibition assay results
(see Figure 2D), perhaps due to the slightly more lipophilic nature
of FR900098 compared to Fos (see Figure 1 for structures), which
may allow some bacterial penetration.
BIOINFORMATIC IDENTIFICATION OF GlpT
The glpT coding region (GlpT) was identified in the F. tularen-
sis tularensis SchuS4 (FTT0725c) and F. novicida (FTN_0636)
genome (accession numbers YP_169738.1 and YP_898283.1)
via BLAST search using the E. coli K12 homologous sequence
(accession number NP_416743.1) as the query. All other Fran-
cisella sequences also have a highly conserved glpT homolog
(e.g., FTM_1358, FTW_1513, FTF0725c, FTA_1594, FTH_1462,
FTL_1510, Fphi_0200). In addition, bioinformatics examination
of Francisella genomes revealed no homologous gene for fsr, an
efflux pump responsible for removal of the Fos fromE. coli (Messi-
aen et al., 2011). Also, by our bioinformatic analysis, the published
genomes for F. novicida, F. tularensis Schu S4, and F. tularen-
sis LVS also do not contain the uhpT transporter (an alternate
transporter that could substitute for glpT ), although the related
species F. philomiragia, which has an environmental habitat and is
not a known pathogen for humans, has a gene that may be uhpT
(Fphi_0883).
SEQUENCING OF glpT IN THE FosR COLONIES
In order to examine the sequence of glpT in the FosR colonies, we
isolated the glpT region by PCR and sequenced glpT from four
different spontaneous FosR colonies. Colonies were picked and
grown in liquid culture overnight in TSB-C to create stocks and
small aliquots were removed for genomic DNA preparation and
sequencing of glpT. Comparison of sequences of the four selected
FosR mutants with wild-type sequence data reveals an array of
nucleotide deletions and additions from various portions of the
glpT gene (Figure 5; Figure A1 in Appendix). The 14 nucleotide
deletion from mutant FnFosR#2 results in a deletion of amino
FIGURE 4 | Sensitivity of wild-type F. novicida and glpT transposon
insertion mutants to fosmidomycin, FR900098, and compound 1.
Sensitivity of F. novicida is shown to all three compounds, to fosmidomycin
(white bar), FR900098 (gray bar), and the lipophilic prodrug of FR900098, or
compound 1 (black bar). Fosmidomycin, FR900098, and compound 1 were
tested at concentrations of 200µg/ml. Resistance of glpT transposon
insertion mutants to fosmidomycin (white bar) and to a lesser extent
FR900098 (gray bar), but not compound 1 (black bar) is shown. No inhibition
was seen using fosmidomycin and the transposon mutants. For this
experiment, n=3 and error bars represent SEM, and in some cases are too
small to be seen.
acids in the translated protein as well as the formation of addi-
tional stop codons. Similarly, the addition of two nucleotides and
one nucleotide in FnFosR#1 and FnFosR#3, respectively, results in
missense mutation by amino acid substitutions and the appear-
ance of premature stop codons resulting in truncated proteins.
These abbreviated proteins are likely non-functional. FnFosR#4
has a single deletion of six nucleotides at position 1126 of the
open reading frame, corresponding to the deletion of a Leu347 and
Ser348 amino acid residues in the protein (Figure 5; Figure A2
in Appendix). When the amino acid sequence of GlpT from the
FnFosR#4 is compared with E. coli, the deleted amino acids occur
in a region that is analogous to a peripheral alpha-helix number
H9 that spans the lipid membrane (Lemieux et al., 2005) but is
not associated with the formation of the pore through which Fos
is transported into the cell.
RATE AND FREQUENCY OF FOSMIDOMYCIN RESISTANCE OF F. novicida
We determined the rate and frequency of FosR of F. novicida. Using
the Drake (1969) formula, the mutation frequency (f) and the
mutation rate (µ) resulting in F. novicida FosR are approximately
6.3× 10−8 and 0.173, respectively. The f is defined as the number
of observed colonies in the presence of the inhibitor divided by the
total number of cells in culture (N t). The µ is determined by the
number of observed colonies (m), the frequency of mutation (f),
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FIGURE 5 | Sequence of FosR F. novicida glpT vs.WT. DNA Sequencing of
the entire ORF for glpT from F. novicida reveals nucleotide deletions and
additions that result in missense frame shifts and stop codon insertion
mutations from isolated colonies grown in the presence of fosmidomycin.
GlpT transposon mutants are shown for comparison (Gallagher et al., 2007).
(A) FnFosR#1 – GC insertion at nt 401/402 results in frame shift after Try133 and
stop codon insert at nt 418/420. FnFosR#2 – 14 bp deletions at nt 216 results in
frame shift at Ala72 and stop codon insert at nt 238/240. FnFosR#3 – G
insertions at nt 517 results in frame shift after Val171 and stop codon insert at
541/543. FnFosR#4 – 6 bp deletion at nt 1042 results in deletion of Ser346 and
Leu347 from the alpha-helix H9. (B) Resulting amino acid alignment from the
FosR mutants vs. WT F. novicida U112.
Table 1 | Frequency of mutants resistant to fosmidomycin (122µM)
from the wild-type strain of F. novicida U112.
Total bacteria (N t) Resistant colonies Frequency (f ) Rate (µ)
4.81×1010 270
5.18×1010 1500
3.66×1010 2310 6.3×10−8 0.173
3.96×1010 2520
4.17×1010 2820
First column represents five different aliquots of bacterial culture as described,
and the second column represents the number of resistant colonies obtained
when plated on 122µM fosmidomycin. Bold signifies the value selected to
determine Rate and Frequency.
and the N t (Table 1). Similarly, the rate determined by the Maxi-
mum Likelihood Method is 0.211 (95% CI= 0.159–0.268; Rosche
and Foster, 2000).
DISCUSSION
Francisella DXR is inhibited by Fos and FR900098. We have previ-
ously established that Fos inhibits purified DXR from F. tularensis
LVS with half maximal activity of 247 nM (Jawaid et al., 2009),
comparable to its effect against DXR fromM. tuberculosis (310 nM;
Dhiman et al., 2005). In addition, we previously demonstrated that
FR900098 was found to have an IC50 of 230 nM against purified
F. tularensis LVS DXR (McKenney et al., in press). In this study,
we have demonstrated the sensitivity of F. tularensis tularensis
(NIHB38) and F. novicida to Fos and FR900098 through the use
of Kirby–Bauer disk-inhibition assays.
Francisella species are sensitive to Fos through their ability
to transport the drug via the glycerol-3-phosphate transporter
(GlpT) and expression of the target enzyme DXR. Spontaneous
mutants (FosR) of Francisella (including Type A) were observed
that contained mutations in glpT, suggesting a transporter-based
mechanism of resistance. Fos has been shown to be effective
against Plasmodium falciparum, the causative agent of malaria
(Jomaa et al., 1999), and some Gram-negative bacteria in vivo (Neu
and Kamimura, 1981). Spontaneous resistance to Fos has been
observed with E. coli (Kanimoto and Greenwood, 1987). Known
mechanisms of resistance to Fos include overexpression of the
target enzymes DXR or IspD (Zhang et al., 2011),overexpression of
efflux pumps (fsr) to remove the drug from the bacterial cell (Mes-
siaen et al., 2011), and mutation or down-regulation of the GlpT
transporter (Fujisaki et al., 1996; Sakamoto et al., 2003; Brown and
Parish, 2008; Messiaen et al., 2011).
The proposed mechanism of resistance to Fos in Burkholderia
cepacia involves both the lack of a functional GlpT transporter
and an increased expression of an efflux pump (fsr) responsi-
ble for removal of the drug from the cell (Messiaen et al., 2011).
Bioinformatics examination of Francisella genomes revealed no
homologous fsr efflux pump. Upon bioinformatic analysis, the
published genomes for F. novicida, F. tularensis Schu S4, and
F. tularensis LVS also do not contain the uhpT transporter (an
alternate transporter that could substitute for glpT ), although the
related environmental species F. philomiragia does appear to have
uhpT. The reason for this difference is unknown.
Thus, the discovery and development of transporter-
independent Fos derivatives could represent a viable strategy to
combat zoonotic bacterial infections, or microbes that have been
developed as bioweapons. Although Staphylococcus aureus and
some other organisms lack a functional DXR homolog, bacte-
ria that contain DXR include B. anthracis (Ravel et al., 2009) and
Y. pestis (Pieper et al., 2008). FosR is perhaps surprising to see
in Francisella given that there is little evidence that spontaneous
resistance to other antimicrobials occurs readily in this organism
(Kormilitsyna and Marakusha, 1983).
1-Deoxy-d-xylulose 5-phosphate reductoisomerase is an essen-
tial enzyme in organisms that use the MEP pathway, as mutations
have been shown to be lethal (Gallagher et al., 2007; Brown and
Parish, 2008). For this reason, antibiotics that target DXR have a
great potential as broad-spectrum therapeutics. While mutations
could occur in the DXR active site that would alter drug activity,
complete knockouts of this enzyme are unlikely due to it being
an essential enzyme. Interestingly, there were no breakthrough
colonies observed in the disk assays with the glpT transposon
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mutants, suggesting that this locus may be responsible for the rel-
atively high number of breakthrough colonies observed with the
wild-type F. novicida. This finding suggests that mutations of DXR
do not readily occur, even under selection with Fos, supporting
the use of DXR as a validated target for future antimicrobial drug
development. This also supports the study of lipophilic prodrugs
such as compound 1 as potential broad-spectrum antimicrobial
compounds (Obiol-Pardo et al., 2011; Uh et al., 2011; Ponaire
et al., 2012).
It is shown here that mutations in the glpT gene can render F.
novicida resistant to high levels of Fos (both FosR and glpT trans-
poson insertion mutants). This is supported by the data showing
that the transposon insertion mutants of glpT are also resistant to
Fos. By using the lipophilic prodrug of FR900098 (compound 1),
it is evident that both the spontaneous glpT transposon insertion
mutants and FosR mutants are still susceptible to compound 1,
consistent with its transporter-independent mechanism of entry
into the bacteria. This result also suggests that the spontaneous
resistance is not due to mutations in DXR, the intracellular bacte-
rial target of Fos, FR900098, and compound 1. It has recently been
shown that Fos also targets the enzyme following DXR in the MEP
pathway, 2-C-methylerythritol-4-phoshpate cytidyltransferase (or
IspD) in E. coli and P. falciparum (Zhang et al., 2011). This is a
promising discovery, as there is a lower frequency of resistance to
antibiotics that have multiple targets (Silver, 2011).
Developing novel therapeutics based on lipophilic derivatives
of phosphonic acids such as Fos and FR900098 represents a new
approach to antimicrobial development with the potential for
broad-spectrum activity against various zoonotic agents (Ort-
mann et al., 2003; Jawaid et al., 2009; Wiemer et al., 2010; Davey
et al., 2011). Compound 1 was recently shown to be effective
against a wide range of bacteria (Obiol-Pardo et al., 2011; Uh
et al., 2011; Ponaire et al., 2012). Such compounds may also
be effective against many biothreat agents (Jawaid et al., 2009).
The conservation of DXR and glpT in the genus Francisella sug-
gests that transporter-dependence of any Fos-derived compounds
should be considered early in the development of these com-
pounds as potential antibiotics. Furthermore, the development
of such compounds to be transporter-independent would be
most desirable. Importantly, these compounds would retain their
effectiveness against strains that may be engineered for other
mechanisms of antimicrobial resistance due to the fundamental
requirement for DXR in most bacterial biothreat agents.
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APPENDIX
FIGUREA1 | Continued
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FIGUREA1 | Full DNA sequence data for FosR mutants vs.WT F. novicida. Detailed sequence results demonstrating the deletion and addition of nucleotides
in a variety of locations in the full length open reading frame compared to the WT F. novicida glpT gene.
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FIGUREA2 | Full amino acid sequence data for FosR mutants vs.WT F. novicida.Translation of the full length DNA sequences including the positions of
amino acid substitution and appearance of early stop codon insertions.
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